103 related articles for article (PubMed ID: 30300611)
21. Prognostic significance of immunohistochemical RhoA expression on survival in pancreatic ductal adenocarcinoma: a high-throughput analysis.
Dittert DD; Kielisch C; Alldinger I; Zietz C; Meyer W; Dobrowolski F; Saeger HD; Baretton GB
Hum Pathol; 2008 Jul; 39(7):1002-10. PubMed ID: 18495213
[TBL] [Abstract][Full Text] [Related]
22. Cystic papillary pattern in pancreatic ductal adenocarcinoma: a heretofore undescribed morphologic pattern that mimics intraductal papillary mucinous carcinoma.
Kelly PJ; Shinagare S; Sainani N; Hong X; Ferrone C; Yilmaz O; Fernández-del Castillo C; Lauwers GY; Deshpande V
Am J Surg Pathol; 2012 May; 36(5):696-701. PubMed ID: 22367300
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel predictive markers for the prognosis of pancreatic ductal adenocarcinoma.
Luo Y; Qiu Z; Tian L; Zhu G; Feng Y; Yi M; Chen X; Wang L; Li C; Huang Q
Hum Pathol; 2013 Jan; 44(1):69-76. PubMed ID: 22939953
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma.
Nitori N; Ino Y; Nakanishi Y; Yamada T; Honda K; Yanagihara K; Kosuge T; Kanai Y; Kitajima M; Hirohashi S
Clin Cancer Res; 2005 Apr; 11(7):2531-9. PubMed ID: 15814630
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma.
Liu C; Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
Cancer Biomark; 2015; 15(6):735-43. PubMed ID: 26406402
[TBL] [Abstract][Full Text] [Related]
26. L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma.
Tsutsumi S; Morohashi S; Kudo Y; Akasaka H; Ogasawara H; Ono M; Takasugi K; Ishido K; Hakamada K; Kijima H
J Surg Oncol; 2011 Jun; 103(7):669-73. PubMed ID: 21360711
[TBL] [Abstract][Full Text] [Related]
27. Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival.
Soeth E; Grigoleit U; Moellmann B; Röder C; Schniewind B; Kremer B; Kalthoff H; Vogel I
J Cancer Res Clin Oncol; 2005 Oct; 131(10):669-76. PubMed ID: 16136352
[TBL] [Abstract][Full Text] [Related]
28. Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features.
Zhao L; Cui Q; Lu Z; Chen J
Pancreas; 2012 Mar; 41(2):206-11. PubMed ID: 21792082
[TBL] [Abstract][Full Text] [Related]
29. Do the Well Known Prognostic Parameters in Pancreatic Ductal Adenocarcinoma Really Reflect Survival?
Öztürk SK; Erden E
Turk Patoloji Derg; 2018; 34(2):127-133. PubMed ID: 28984346
[TBL] [Abstract][Full Text] [Related]
30. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.
Richter A; Niedergethmann M; Sturm JW; Lorenz D; Post S; Trede M
World J Surg; 2003 Mar; 27(3):324-9. PubMed ID: 12607060
[TBL] [Abstract][Full Text] [Related]
31. Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules.
Gandou C; Harada K; Sato Y; Igarashi S; Sasaki M; Ikeda H; Nakanuma Y
Hum Pathol; 2013 May; 44(5):811-21. PubMed ID: 23134772
[TBL] [Abstract][Full Text] [Related]
32. Negative impact of fresh-frozen plasma transfusion on prognosis of pancreatic ductal adenocarcinoma after pancreatic resection.
Shiba H; Misawa T; Fujiwara Y; Futagawa Y; Furukawa K; Haruki K; Iida T; Iwase R; Yanaga K
Anticancer Res; 2013 Sep; 33(9):4041-7. PubMed ID: 24023348
[TBL] [Abstract][Full Text] [Related]
33. Pancreatic Ductal Adenocarcinoma and Its Variants.
Luchini C; Capelli P; Scarpa A
Surg Pathol Clin; 2016 Dec; 9(4):547-560. PubMed ID: 27926359
[TBL] [Abstract][Full Text] [Related]
34. Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma.
Robinson SM; Rahman A; Haugk B; French JJ; Manas DM; Jaques BC; Charnley RM; White SA
Eur J Surg Oncol; 2012 Apr; 38(4):333-9. PubMed ID: 22317758
[TBL] [Abstract][Full Text] [Related]
35. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
Sclafani F; Iyer R; Cunningham D; Starling N
Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
[TBL] [Abstract][Full Text] [Related]
36. Prognostic and predictive markers in pancreatic adenocarcinoma.
Le N; Sund M; Vinci A;
Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
[TBL] [Abstract][Full Text] [Related]
37. Epithelial and stromal expression of syndecan-2 in pancreatic carcinoma.
Hrabar D; Aralica G; Gomercic M; Ljubicic N; Kruslin B; Tomas D
Anticancer Res; 2010 Jul; 30(7):2749-53. PubMed ID: 20683009
[TBL] [Abstract][Full Text] [Related]
38. The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer.
Hu H; Hang JJ; Han T; Zhuo M; Jiao F; Wang LW
Tumour Biol; 2016 Jul; 37(7):8657-64. PubMed ID: 26738860
[TBL] [Abstract][Full Text] [Related]
39. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract][Full Text] [Related]
40. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN.
Yamaguchi K; Kanemitsu S; Hatori T; Maguchi H; Shimizu Y; Tada M; Nakagohri T; Hanada K; Osanai M; Noda Y; Nakaizumi A; Furukawa T; Ban S; Nobukawa B; Kato Y; Tanaka M
Pancreas; 2011 May; 40(4):571-80. PubMed ID: 21499212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
